Your SlideShare is downloading. ×
Multiple  myeloma
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Multiple myeloma


Published on

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 2. Most common primary malignant tumor of bone. Multiple myeloma is a malignant clonal proliferation of plasma cells in the bone marrow with lytic bone leisions.
  • 3. TYPES Multiple myeloma (50%) Solitary myeloma (25%) Myelomatosis (15%) Plasma cell leukemia (1%) Extra skeletal - nasopharyngeal / oral cavity
  • 4. EPIDEMIOLOGY Age group : 50 – 60 yrs Sex : M:F- 3:1 Site : common in axial skeleton & flat bones than long bones. - spine , skull, pelvis , ribs , sternum, proximal femur
  • 5. CLINICAL FEATURES Bone pain is the most common symptom , which is relieved by rest. Persistent localised bone pain signifies pathological fracture. No swelling / deformity unless there is pathologic al # Compressive myelopathy due to vertebral collapse .
  • 6. CLINICAL HALLMARKS OF MM Weight loss , pallor, bleeding tendencies, fatigue Susceptibility to bacterial infections Hypercalcemia Renal failure Bone destructions lytic lesions) Presence monoclonal antibody
  • 7. INVESTIGATIONS Haemogram shows anaemia , leucopenia , thrombocytopenia ESR is very high Peripheral smear – NCNA with increased rouleaux formation. Leucoerythroblastic picture. Total protein increased with A:G reversal. S.Ca is increased, ALP normal.
  • 8. Electrophoresis on serum or urine shows ‘M’ band in the region of gamma globulin. Urine may show Bence Jones protein. Bone marrow – hypercellular with increased no. of plasma cells & myeloma cells. Mature & Immature plasma cells with eccenteric nuclei and ‘cart- wheel appearance’ of nuclear chromatin
  • 9. RADIOLOGICAL FINDINGS Multiple punched out lesions in skull & other flat bones.
  • 10. M M with pathological #
  • 11. Pathological wedge collapse of vertebra, commonly thoracic spine. Pedicles usually spared. Diffuse severe rarefaction of bones. Erosion of borders of ribs.
  • 12. CT & MRI Bone scan in solitarybone lesions helps to detect other sites of involvement. S. beta 2 microglogulin is the single most powerful predictor of survival.
  • 13. DIAGNOSTIC CRITERIA (DURIE & SALMON) Major criteria 1.BM plasmacytosis ( > or = 30% BM plasma cells) 2.Monoclonal globulin spike Ig G or Ig A 3.Light chain excretion in urine ; > or = 1g/24 hrs. 4.Biopsy proven plasmacytoma
  • 14. Minor criterias 1.BM plasmacytosis ; 10-30 % BM plasma cells 2.Monoclonal globulin spike gut < for major criteria. 3.Lytic bone lesions 4.Decrease in normal Ig level. Diagnosis - I major + 1 minor criteria 3 minor criteria that must include no. 1& no.2
  • 15. TREATMENT “Watchful waiting", where the progress of the disease is monitored . Chemotherapy • Melphalan, prednisone, thalidomide (MPT) • Bortezomib (Velcade), melphalan, prednisone (VMP) • Lenalidomide plus low-dose dexamethasone • Every 3-4 weeks for 6-12 cycles.
  • 16. Radiotherapy • Severe bone pain , pathological # , tumor lesions. Bone marrow transplantation Bisphosphonates (e.g. pamidronate or zoledronic acid) are routinely administered to prevent fractures and erythropoietin to treat anemia.
  • 17. Pathological # prevented by internal splinting of affected part. #s managed surgically by internal fixation . Treatment of other complications. In established cases survival is 2-3 yrs